Pay in 4 interest-free payments of $5.54 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Coya said the trial met its primary endpoint for safety and secondary endpoint for regulatory T cell (Treg) cell population enhancement, with no off-target effects on T effector lymphocytes, providing further evidence of target engagement in 22 patients dosed with five days of LD IL-2 (106 IU/day) or placebo every four weeks for 21 weeks
difficile following C12:0 treatment
Due to different lot activities, lower concentration of Nuclease P1 (0.006 U/g total RNA) was used here, compared to the experiment presented in Fig
The vial labels looked professional and the order was packed with care
LongLPangX-XLeiFZhangJ-SWangWLiaoL-Det al
the trials escalated deliberately, and the tolerability data is the reason
US$ 24.23
US$ 27.46
